Q32 Bio director Mark Iwicki to resign from board, effective Dec 31, 2025

Q32 Bio Inc.

Mark Iwicki notified his resignation from the board on April 25, 2025, effective December 31, 2025.
He will remain Chair and Compensation Committee chair, and Audit Committee member until the effective date.
Resignation is to reduce board commitments; no disagreement with the company.
He will continue as CEO of Inhibikase Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Iwicki

Director

QTTB · Q32 Bio Inc.

Effective: 2025-12-31
Filed: April 25, 2025, 7:59 PM ET

On April 25, 2025, Mark Iwicki provided notice of his resignation from the board of directors (the “Board”) of Q32 Bio Inc. (the “Company”), effective as of December 31, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Iwicki resigned as Director at Q32 Bio Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 25, 2025, Mark Iwicki provided notice of his resignation from the board of directors (the “Board”) of Q32 Bio Inc. (the “Company”), effective as of December 31, 2025

View on SEC.gov

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-096703

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.